Post Thumb

Juno pulls the plug on a once-promising cancer treatment

J uno Therapeutics is abandoning a cancer therapy that once looked like a revolutionary advance, reacting to a rash of patient deaths that made the customized treatment too risky to push forward. The company’s decision changes the landscape in a blockbuster race to commercialize the first CAR-T technology, a promising new approach to cancer in which …